The effect of intravitreal injections of Lucentis (ranibizumab) on retinal function in diabetic patients with diabetic macular edema and visual impairment [Effekten av, i glaskroppen injicerat läkemedel, Lucentis (ranibizumab) på näthinnans funktion hos diabetiker med synförsämring till följd av diabetiskt maculaödem]

Trial Profile

The effect of intravitreal injections of Lucentis (ranibizumab) on retinal function in diabetic patients with diabetic macular edema and visual impairment [Effekten av, i glaskroppen injicerat läkemedel, Lucentis (ranibizumab) på näthinnans funktion hos diabetiker med synförsämring till följd av diabetiskt maculaödem]

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 06 Nov 2012

At a glance

  • Drugs Ranibizumab (Primary)
  • Indications Diabetic macular oedema
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 25 Mar 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top